HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Cosmetics Office Shifts Focus As Bioterrorism, BSE Take Priority

This article was originally published in The Rose Sheet

Executive Summary

FDA initiatives to counter potential bioterrorism through agency-regulated products - including cosmetics - have prompted a priority shift for the agency's Office of Cosmetics & Colors, Division of Science and Applied Technology Director Adele Dennis, PhD, said

You may also be interested in...



CTFA Monitoring Bioterrorism Legislation To Preserve Self-Regulation

Bioterrorism legislation under review by Congress has the potential to spark additional regulation within the cosmetics industry, Cosmetic, Toiletry and Fragrance Association Legislative Relations VP Michael Thompson said during the trade group's annual meeting in Boca Raton, Fla. Feb. 28-March 3

CTFA Monitoring Bioterrorism Legislation To Preserve Self-Regulation

Bioterrorism legislation under review by Congress has the potential to spark additional regulation within the cosmetics industry, Cosmetic, Toiletry and Fragrance Association Legislative Relations VP Michael Thompson said during the trade group's annual meeting in Boca Raton, Fla. Feb. 28-March 3

FDA Cosmetics Office Aims To Achieve Three “A” List Priorities In 2002

FDA's Office of Cosmetics & Colors will tackle three "A" list items and 10 "B" list goals in fiscal 2002 under the Center for Food Safety & Applied Nutrition's program priorities report issued Jan. 28

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel